Incretin hormones, insulin, glucagon and advanced glycation end products in relation to cognitive function in older people with and without diabetes, a population‐based study

The aim of this observational study was to investigate relationships between physiological levels of glucometabolic biomarkers and cognitive test results in a population‐based setting.

[1]  E. Classon,et al.  A quick test of cognitive speed (AQT): regression-based norms for cognitively healthy 80 to 94-year olds , 2021, Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.

[2]  J. Rungby,et al.  Antidiabetic medication and risk of dementia in patients with type 2 diabetes. A nested case-control study. , 2019, European journal of endocrinology.

[3]  B. Zinman,et al.  Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial , 2019, Diabetes Care.

[4]  Blair H. Smith,et al.  Insulin resistance: Genetic associations with depression and cognition in population based cohorts , 2019, Experimental Neurology.

[5]  G. Biessels,et al.  Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications , 2018, Nature Reviews Endocrinology.

[6]  A. Surolia,et al.  Insulin signaling pathway protects neuronal cell lines by Sirt3 mediated IRS2 activation , 2018, BioFactors.

[7]  Steven E. Arnold,et al.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums , 2018, Nature Reviews Neurology.

[8]  V. Gault.  RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes , 2018, Diabetic medicine : a journal of the British Diabetic Association.

[9]  W. M. van der Flier,et al.  Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease , 2017, Journal of Alzheimer's disease : JAD.

[10]  J. Zhu,et al.  Enhanced AMPA Receptor Trafficking Mediates the Anorexigenic Effect of Endogenous Glucagon-like Peptide-1 in the Paraventricular Hypothalamus , 2017, Neuron.

[11]  K. Blennow,et al.  Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype , 2017, Neurobiology of Aging.

[12]  I. Kåreholt,et al.  Validation of abridged mini-mental state examination scales using population-based data from Sweden and USA , 2016, European Journal of Ageing.

[13]  A. Gjedde,et al.  In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial , 2016, Front. Aging Neurosci..

[14]  Liang-Jun Yan,et al.  Role of RAGE in Alzheimer’s Disease , 2015, Cellular and Molecular Neurobiology.

[15]  Hubert Preissl,et al.  Impaired insulin action in the human brain: causes and metabolic consequences , 2015, Nature Reviews Endocrinology.

[16]  O. Melander,et al.  Risk factors for the progression of carotid intima-media thickness over a 16-year follow-up period: the Malmö Diet and Cancer Study. , 2015, Atherosclerosis.

[17]  P. Dagnelie,et al.  Associations of advanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes: the maastricht study. , 2015, The Journal of clinical endocrinology and metabolism.

[18]  H. Amièva,et al.  Normalized Mini-Mental State Examination for Assessing Cognitive Change in Population-Based Brain Aging Studies , 2014, Neuroepidemiology.

[19]  C. Hölscher.  The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease , 2014, Alzheimer's & Dementia.

[20]  C. Hölscher,et al.  Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model , 2013, Alzheimer's Research & Therapy.

[21]  E. Vittinghoff,et al.  Advanced glycation end product level, diabetes, and accelerated cognitive aging , 2011, Neurology.

[22]  C. Deacon,et al.  Physiology of incretins in health and disease. , 2011, The review of diabetic studies : RDS.

[23]  Lars Bäckman,et al.  Accelerated Progression From Mild Cognitive Impairment to Dementia in People With Diabetes , 2010, Alzheimer's & Dementia.

[24]  J. Holst.  The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.

[25]  R. Gans,et al.  Simple non-invasive assessment of advanced glycation endproduct accumulation , 2004, Diabetologia.

[26]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[27]  G. Berglund,et al.  The Malmö diet and cancer study: representativity, cancer incidence and mortality in participants and non‐participants , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[28]  N. Schneiderman,et al.  Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. , 2000, Diabetes research and clinical practice.

[29]  P. J. Larsen,et al.  Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem , 1997, Neuroscience.

[30]  N. Hoosein,et al.  Identification of glucagon receptors in rat brain. , 1984, Proceedings of the National Academy of Sciences of the United States of America.